Acute kidney injury in diabetic patients: clinical course and prognosis

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Currently, more than 537 million people worldwide suffer from type 2 diabetes mellitus (DM2), and this number is projected to increase to 783 million by 2045. Among the chronic DM2complications, diabetic microangiopathy and nephropathy occupy a special place. Albuminuria, podocinuria, and nephrinuria are considered early preclinical markers of kidney damage in DM2. Clinical forms of kidney damage in DM2 include acute kidney injury (AKI), acute kidney disease, chronic kidney disease (CKD), and others. Risk factors for the development of AKI in DM2 patients include advanced age, male gender, long-term disease, uncontrolled glycemic profile, arterial hypertension, short-term exposure to extreme heat, infectious and inflammatory processes, the presence of CKD, and others. The development of acute kidney injury (AKI) in DM2 worsens the long-term prognosis and increases the risk of in-hospital mortality.

Description of the clinical case. This article presents the results of a clinical folloew-up of patient R., 66, with AKI that developed against the background of type 2 diabetes mellitus. It is demonstrated that timely diagnosis and treatment of AKI can lead to a favorable outcome. During the patient’s follow-up, serum biomarkers—creatinine and cystatin C—were used to assess renal function.

About the authors

Ilkhom T. Murkamilov

Kyrgyz State Medical Academy named after I.K. Akhunbaev; Salymbekov University

Author for correspondence.
Email: murkamilov.i@mail.ru
ORCID iD: 0000-0001-8513-9279

Dr.Sci. (Med.), Corresponding Member of the Russian Academy of Natural Sciences, Associate Professor, Department of Faculty Therapy, Kyrgyz State Medical Academy named after. I.K. Akhunbaev, Director of the Multidisciplinary Medical Center “Doc University Clinic”, Salymbekov University

Kyrgyzstan, Bishkek; Bishkek

Kubanich A. Aitbaev

Salymbekov University

Email: aitbaev.kuban1940@gmail.com
ORCID iD: 0000-0003-4973-039X

Dr.Sci. (Med.), Professor, Consultant of the Department of Resuscitation, Therapy, and Diagnostics, Multidisciplinary Medical Center “Salymbekov University”

Kyrgyzstan, Bishkek

Viktor V. Fomin

Russian Medical Academy of Continuous Professional Education

Email: fomin_vic@mail.ru
ORCID iD: 0000-0002-2682-4417

Dr.Sci. (Med.), Professor, Academician of the Russian Academy of Sciences, Rector

Russian Federation, Moscow

Zafarbek R. Raimzhanov

N.N. Burdenko Main Military Clinical Hospital

Email: rzrmam@mail.ru
ORCID iD: 0000-0001-5746-6731

Neurologist, 29th Department of Neurology

Russian Federation, Moscow

Furkat A. Yusupov

Osh State University

Email: furcat_y@mail.ru
ORCID iD: 0000-0003-0632-6653

Dr.Sci. (Med.), Professor, Head of the Department of Neurology, Neurosurgery, and Psychiatry, Faculty of Medicine

Kyrgyzstan, Osh

Tursunoy F. Yusupova

Osh State University

Email: yusupova_tursunoy_f@mail.ru
ORCID iD: 0000-0002-8502-2203

Clinical Resident, Department of Neurology, Neurosurgery, and Psychiatry, Faculty of Medicine

Kyrgyzstan, Osh

Abdulkhokim F. Yusupov

Osh State University

Email: furcat_y@mail.ru

Assistant Professor, Department of Neurology, Neurosurgery, and Psychiatry, Faculty of Medicine

Kyrgyzstan, Osh

Zhaloliddin I. Solizhonov

Republican Specialized Scientific and Practical Medical Center for Nephrology and Kidney Transplantation

Email: jaloliddinsolijonov44@gmail.com
ORCID iD: 0009-0003-0078-0609

clinical resident

Uzbekistan, Tashkent

Komil K. Khabibullaev

Kyrgyz State Medical Academy named after I.K. Akhunbaev

Email: khabibullaevkomil2001@gmail.com
ORCID iD: 0009-0004-5508-8019

Resident Doctor

Kyrgyzstan, Bishkek

References

  1. Hossain M.J., Al-Mamun M., Islam M.R. Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused. Health Sci. Rep. 2024;7(3):e2004. doi: 10.1002/hsr2.2004.
  2. Borhade M.B., Yashi K., Singh S. Diabetes and Exercise. 2025 Feb 26. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2025 Jan. [PMID: 30252351].
  3. Дедов И.И., Шестакова М.В., Викулова О.К. и др. Эпидемиология и ключевые клинико-терапевтические показатели сахарного диабета в Российской Федерации в разрезе стратегических целей Всемирной организации здравоохранения. Сахарный диабет. 2025;28(1):4–17. [Dedov I.I., Shestakova M.V., Vikulova O.K. et al. Epidemiology and key clinical and therapeutic indicators of diabetes mellitus in Russian Federation according to the World Health Organization’s strategy goals. Diab. Mellitus. 2025;28(1):4–17 (In Russ.)]. doi: 10.14341/DM13292.
  4. Камышова Е.С., Бобкова И.Н., Кутырина И.М. Современные представления о роли микроРНК при диабетической нефропатии: потенциальные биомаркеры и мишени таргетной терапии. Сахарный диабет.2017;20(1):42–50. doi: 10.14341/DM8237. [Kamyshova E.S., Bobkova I.N., Kutyrina I.M. New insights on microRNAs in diabetic nephropathy: potential biomarkers for diagnosis and therapeutic targets. Diab. Mellitus. 2017;20(1):42–50 (In Russ.)]. doi: 10.14341/DM8237.
  5. Бобкова И.Н., Щукина А.А., Шестакова М.В. Клиническое значение определения экскреции с мочой нефрина и подоцина у больных сахарным диабетом. Клиническая фармакология и терапия. 2017;26(5):31–6. [Bobkova I., Shchukina A., Shestakova M. Clinical significance of nephrin and podocin urinary excretion in patients with diabetes mellitus. Clin. Pharmacol. Ther. 2017;26(5):31–6 (In Russ.)].
  6. Guo J., Wei M., Zhang W. et al. Clinical efficacy and safety of sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist, and Finerenone in type 2 diabetes mellitus with non-dialysis chronic kidney disease: a network meta-analysis of randomized clinical trials. Front. Pharmacol. 2025;16:1517272. doi: 10.3389/fphar.2025.1517272.
  7. Клинические рекомендации. Хроническая болезнь почек (ХБП). Нефрология. 2021;25(5):10–82. doi: 10.36485/1561-6274-2021-25-5-10-82. [Clinical recommendations. Chronic kidney disease (CKD). Nephrology (Saint-Petersburg). 2021;25(5):10–82 (In Russ.)]. doi: 10.36485/1561-6274-2021-25-5-10-82.
  8. Курбатов Д.Г., Дубский С.А., Лепетухин А.Е. и др. Симптоматика, диагностика и лечение острых воспалительных заболеваний почек у больных сахарным диабетом. Сахарный диабет. 2009;12(2):72–6. doi: 10.14341/2072-0351-5403. [Kurbatov D.G., Dubsky S.A., Lepetukhn A.E., et al. Symptomatology diagnosis and treatment of acute inflammatory renal diseases in diabetic patients. Diab. Mellitus. 2009;12(2):72–6 (In Russ.)]. doi: 10.14341/2072-0351-5403.
  9. Смирнов А.В., Добронравов В.А., Румянцев А.Ш. и др. Национальные рекомендации. Острое повреждение почек: основные принципы диагностики, профилактики и терапии. Часть I. Нефрология. 2016;20(1):79–104. [Smirnov A.V., Dobronravov V.A., Rumyantsev A.Sh. et al. National guidelines acute kidney injury: basic principles of diagnosis, prevention and therapy. Part I. Nephrology (Saint-Petersburg). 2016;20(1):79–104 (In Russ.)]. doi: 10.24884/1561-6274-2016-20-1-8-15.
  10. Сумин А.Н., Безденежных Н.А., Безденежных А.В. и др. Фильтрационная функция почек и сахарный диабет 2-го типа как предикторы послеоперационных осложнений коронарного шунтирования. Кардиология и сердечно-сосудистая хирургия. 2015;8(1):1725. [Sumin A.N., Bezdenezhnykh N.A., Bezdenezhnykh A.V. et al. The filtration renal function and diabetes mellitus type 2 as predictors of postoperative complications after coronary artery bypass grafting. Rus. J. Cardiol. Cardiovasc. Surg. 2015;8(1):1725. (In Russ.)]. doi: 10.17116/kardio20158117-25.
  11. Shi K., Jiang W., Song L. et al. Persistent acute kidney injury biomarkers: A systematic review and meta-analysis. Clin. Chim. Acta. 2025;564:119907. doi: 10.1016/j.cca.2024.119907.
  12. Saha R., Sharma S., Mondal A. et al. Evaluation of Acute Kidney Injury (AKI) Biomarkers FABP1, NGAL, Cystatin C and IL-18 in an Indian Cohort of Hospitalized Acute-on-chronic Liver Failure (ACLF) Patients. J. Clin. Exp. Hepatol. 2025;15(3):102491. doi: 10.1016/j.jceh.2024.102491.
  13. Inker L.A., Eneanya N.D., Coresh J. et al. Chronic Kidney Disease Epidemiology Collaboration. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N. Engl. J. Med. 2021;385(19):1737–49. doi: 10.1056/NEJMoa2102953.
  14. Delanaye P., Flamant M., Vidal-Petiot E. et al. Discordant Results Between Creatinine- and Cystatin C-based Equations for Estimating GFR. Kidney Int. Rep. 2025;10(4):1248–59. doi: 10.1016/j.ekir.2025.01.030.
  15. Муркамилов И.Т., Айтбаев К.А., Фомин В.В., Муркамилова Ж.А. Цистатин С как маркер хронической болезни почек. Терапия. 2019;5(4):57–62. [Murkamilov I.T., Aitbaev K., Fomin V.V., Murkamilova ZH.A. Cystatin C as a marker of chronic kidney desease. Therapy. 2019;5(4):57–62 (In Russ.)].
  16. Муркамилов И.Т., Айтбаев К.А., Фомин В.В. и др. Поражения почек при гипертонической болезни. Клиническая медицина. 2023;101(11):569–76. doi: 10.30629/0023-2149-2023-101-11-569-576. [Murkamilov I.T., Aitbaev K.A., Fomin V.V. et al. Kidney dam age in hypertension disease. Klinicheskaya meditsina. 2023;101(11):569–76. (In Russ.)]. doi: 10.30629/0023-2149-2023-101-11-569-576.
  17. Stehlé T., Delanaye P. Which is the best glomerular filtration marker: Creatinine, cystatin C or both? Eur. J. Clin. Invest. 2024;54(10):e14278. doi: 10.1111/eci.14278.
  18. Кирпатовский В.И, Орлова Е.В., Харламова Л.А. и др. Значимость динамического определения концентрации Цистатина С в крови как маркера риска перехода острого повреждения почек в хроническую почечную недостаточность и эффективности нефропротективной терапии. Экспериментальная и клиническая урология 2021;14(4):20–9. [Kirpatovskiy V.I., Orlova E.V., Kharlamova L.A., et al. The significance of dynamic detection of Cystatin C concentration in the blood as a marker of the risk of transition of acute kidney injury to chronic renal failure and the effectiveness of nephroprotective therapy. Exp. Clin. Urology. 2021;14(4):20–9 (In Russ.)]. doi: 10.29188/2222-8543-2021-14-4-20-29.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2026 Bionika Media